DRUGS & THERAPY PERSPECTIVES

Scope & Guideline

Exploring Innovative Pathways in Drug Efficacy

Introduction

Explore the comprehensive scope of DRUGS & THERAPY PERSPECTIVES through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore DRUGS & THERAPY PERSPECTIVES in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1172-0360
PublisherSPRINGERNATURE
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1993 to 2024
AbbreviationDRUGS THER PERSPECT / Drugs. Ther. Perspect.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The journal 'DRUGS & THERAPY PERSPECTIVES' focuses on providing comprehensive insights into the use and management of pharmacological therapies across a variety of medical conditions. Its primary aim is to enhance the understanding of drug therapies, their clinical implications, and the overall therapeutic landscape.
  1. Pharmacotherapy Profiles:
    The journal frequently publishes detailed profiles of existing and emerging pharmacotherapies, highlighting their efficacy, safety, and clinical applications across various diseases.
  2. Clinical Decision-Making:
    Research often emphasizes the role of clinical decision-making in pharmacotherapy, particularly in complex cases such as managing multiple comorbidities in older adults.
  3. Pharmacovigilance and Safety:
    A significant focus is placed on pharmacovigilance, with studies examining adverse drug reactions, medication errors, and the impact of clinical pharmacy services on patient safety.
  4. Emerging Therapies and Innovations:
    The journal covers new and innovative treatments, providing insights into their potential benefits and limitations, which is crucial for clinicians looking to implement cutting-edge therapies.
  5. Healthcare Policy and Access to Medicines:
    Research also addresses healthcare policy issues, including access to medications and the implications of health technology assessments on clinical practice.
Recent publications in 'DRUGS & THERAPY PERSPECTIVES' reveal a shift towards several trending and emerging themes that reflect current challenges and innovations in the field of pharmacotherapy. This section outlines these trends.
  1. Personalized Medicine:
    An increasing number of articles emphasize the importance of personalized medicine, tailoring pharmacotherapy to individual patient needs, particularly in complex cases or chronic conditions.
  2. Management of Chronic Conditions:
    There is a growing focus on the management of chronic conditions such as diabetes, hypertension, and mental health disorders, reflecting the need for more effective long-term treatment strategies.
  3. Pharmacogenomics:
    Research exploring pharmacogenomic approaches to optimizing drug therapy based on genetic profiles is on the rise, indicating a shift towards more precise prescribing practices.
  4. Telehealth and Digital Health Solutions:
    With the rise of telehealth, the journal is increasingly addressing the role of digital health solutions in managing therapy adherence and patient engagement.
  5. Comprehensive Safety Evaluations:
    There is a trend towards more comprehensive evaluations of drug safety, including monitoring long-term effects and interactions, especially in vulnerable populations such as the elderly.

Declining or Waning

While 'DRUGS & THERAPY PERSPECTIVES' continues to explore a broad range of therapeutic areas, certain themes appear to be declining in prominence over recent years. This section highlights these waning scopes.
  1. Traditional Pharmacotherapy:
    There has been a noticeable decrease in articles focusing solely on traditional pharmacotherapy approaches, as the journal shifts towards more innovative and personalized treatment strategies.
  2. Generalized Guidelines for Drug Use:
    Publications that offer generalized treatment guidelines without specific contexts or patient populations are becoming less frequent, reflecting a trend towards more individualized and nuanced approaches to therapy.
  3. Focus on Older Pharmacological Agents:
    Research pertaining to older pharmacological agents is diminishing, possibly as newer therapeutics gain traction and as the focus shifts towards novel treatments and their comparative efficacy.
  4. Single-Agent Therapy Studies:
    There is a waning interest in studies that examine the efficacy of single-agent therapies, with more emphasis now placed on combination therapies and multidisciplinary treatment approaches.

Similar Journals

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Transforming clinical research into therapeutic excellence.
Publisher: WILEY-HINDAWIISSN: 0269-4727Frequency: 1 issue/year

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.

MEDICAL LETTER ON DRUGS AND THERAPEUTICS

Navigating the Complexities of Drug Therapy
Publisher: MED LETTER INCISSN: 0025-732XFrequency: 26 issues/year

MEDICAL LETTER ON DRUGS AND THERAPEUTICS is a pivotal resource for professionals in the fields of medicine and pharmacology, published by MED LETTER INC. Since its inception in 1965, this journal has been committed to elucidating the complexities of drug therapy and clinical therapeutics, offering readers evidence-based insights and critical evaluations of the latest medications and treatment protocols. With a quarterly ranking reflecting its stature—Q4 in Medicine (Miscellaneous) and Q3 in both Pharmacology and Pharmacology (Medical)—the journal maintains a specific niche ensuring readers are equipped with updated information that continues to influence healthcare practices. Although it does not operate under an open access model, the journal is accessible to institutions and professionals eager to stay at the forefront of medicinal advancements. The importance of this journal lies in its dedication to enhancing pharmacological knowledge, thus catering to the needs of researchers, healthcare providers, and students alike, making it an essential addition to the literature in therapeutic drug interventions.

Expert Review of Clinical Pharmacology

Empowering clinicians with the latest in pharmacological advancements.
Publisher: TAYLOR & FRANCIS LTDISSN: 1751-2433Frequency: 12 issues/year

Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Transforming Pharmacology Through Rigorous Research
Publisher: WILEYISSN: 0306-5251Frequency: 12 issues/year

British Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.

PHARMACOTHERAPY

Fostering Excellence in Medical Pharmacology
Publisher: WILEYISSN: 0277-0008Frequency: 12 issues/year

PHARMACOTHERAPY, an esteemed journal published by WILEY, stands as a pivotal resource within the field of medical pharmacology. With its ISSN 0277-0008 and E-ISSN 1875-9114, this journal has been at the forefront of pharmacological research since its inception in 1981. Renowned for its rigorous peer-review process and impactful contributions, it currently holds a prestigious Q1 quartile ranking in the pharmacology category, underscoring its significance as a leading publication in the field. It ranks #40 out of 272 journals in Scopus, placing it in the top 15% percentile of its category. While not an open-access publication, PHARMACOTHERAPY remains committed to advancing knowledge and understanding in pharmacological sciences, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to improving therapeutic outcomes and drug utilization. Based in the United States, at 111 River St, Hoboken, NJ, the journal is poised to continue its impact through to 2024 and beyond, welcoming contributions that further the discourse in pharmacotherapy.

EXPERT OPINION ON INVESTIGATIONAL DRUGS

Illuminating the Path to Next-Generation Treatments
Publisher: TAYLOR & FRANCIS LTDISSN: 1354-3784Frequency: 12 issues/year

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

Current Drug Safety

Elevating Standards in Drug Safety Evaluation
Publisher: BENTHAM SCIENCE PUBLISSN: 1574-8863Frequency: 3 issues/year

Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.

Clinical Pharmacology-Advances and Applications

Catalyzing Collaboration for Pharmacological Excellence
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1438Frequency: 1 issue/year

Clinical Pharmacology-Advances and Applications is a premier open access journal published by DOVE MEDICAL PRESS LTD, based in New Zealand. Since its establishment in 2009, the journal has been dedicated to advancing the field of pharmacology by disseminating innovative research and applications related to medication therapy and patient outcomes. With its notable impact factor and current ranking within the top percentile of pharmacology journals, it provides an invaluable platform for researchers, healthcare professionals, and students to share knowledge and foster collaboration. The journal's content spans a wide range of topics, ensuring coverage of both fundamental and emerging areas in medical pharmacology. As of 2023, it holds a strong position in the Q2 quartile, underscoring its relevance and influence within the scientific community. Authors and readers alike benefit from its open access model, which ensures that critical findings are widely accessible, thereby enhancing the pace of discovery and application in clinical settings.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Transforming vision care with cutting-edge studies.
Publisher: MARY ANN LIEBERT, INCISSN: 1080-7683Frequency: 10 issues/year

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

DRUGS

Transforming Discoveries into Therapeutic Realities
Publisher: ADIS INT LTDISSN: 0012-6667Frequency: 18 issues/year

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.